Enhancement of experimental tumors in mice by treatment with concanavalin A.
Weanling BALB/c mice given injections of 300 micrograms concanavalin A (Con A) prior to and at frequent intervals after challenge with Moloney murine sarcoma virus (M-MuSV), 3-methylcholanthrene (MCA), or TEPC-15 plasmacytoma cells showed an enhancement of tumor induction or development. With the M-MuSV and MCA systems, this enhancement was evidenced by larger tumors and, in the MCA system, by more devastating tumors. Regression of the M-MuSV-induced tumors was more prolonged in Con A-treated mice. With the TEPC-15 system, enhancement was evidenced by a more rapid mortality rate in treated animals.
D000818:Animals; D003208:Concanavalin A / Q000633:toxicity*; D007165:Immunosuppression Therapy; D008297:Male; D008748:Methylcholanthrene; D051379:Mice; D008807:Mice, Inbred BALB C; D008979:Moloney murine leukemia virus; D009374:Neoplasms, Experimental / Q000209:etiology; D010954:Plasmacytoma / Q000209:etiology* / Q000276:immunology; D012513:Sarcoma, Experimental / Q000209:etiology* / Q000276:immunology; D014412:Tumor Virus Infections / Q000209:etiology
D003208:Concanavalin A; D008748:Methylcholanthrene